Business Context and Reporting Period
Allogene Therapeutics, Inc. filed a Form 8-K under Item 5.02 regarding a change in executive leadership. The reported event occurred on December 27, 2022, and the report was signed on January 3, 2023. Allogene is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol ALLO.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Rafael G. Amado, M.D., notified Allogene on December 27, 2022, that he would resign as Executive Vice President of Research and Development.
- His resignation became effective December 30, 2022.
- Dr. Amado resigned to pursue another opportunity.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide updated financial guidance, operating outlook, succession details, compensation terms, severance arrangements, or information regarding the impact of the departure on research and development programs.
Important Facts to Verify
- Confirm the identity and responsibilities of Dr. Amado’s successor or interim replacement.
- Review subsequent filings and company announcements for changes to research and development strategy or program timelines.
- Check whether any resignation-related compensation, severance, or other arrangements were disclosed in later filings.
- Assess any impact on Allogene’s clinical development plans and regulatory milestones.